ANURAS Anupam Rasayan India Q3 FY25 results (Oct–Dec 2024) and concall
Anupam Rasayan reported strong Q3 FY25 results with significant revenue and profit growth, driven by its Pharma and Polymer segments and the Tanfac acquisition. Despite a challenging 9M FY25 due to agrochemical sector headwinds and a customer withdrawal, the company is optimistic about FY26, targeting 30-35% revenue growth. Strategic capex, green energy initiatives, and a robust R&D pipeline underpin future growth, with a focus on geographical and product diversification.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 294 | 390 |
| EBITDA | 80 | 124 |
| Net profit | 31 | 54 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
